X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (9) 9
oncology (9) 9
cancer (8) 8
immunology (7) 7
immunotherapy (6) 6
article (5) 5
kidney neoplasms - therapy (5) 5
chemotherapy (4) 4
female (4) 4
kidney neoplasms - immunology (4) 4
melanoma (4) 4
nivolumab (4) 4
adult (3) 3
carcinoma (3) 3
carcinoma, medullary - therapy (3) 3
case report (3) 3
expression (3) 3
male (3) 3
medicine, research & experimental (3) 3
pd-1 (3) 3
pembrolizumab (3) 3
programmed cell death 1 receptor - antagonists & inhibitors (3) 3
programmed cell death 1 receptor - immunology (3) 3
renal cell carcinoma (3) 3
t cells (3) 3
tumor microenvironment - immunology (3) 3
tumors (3) 3
activation (2) 2
adverse events (2) 2
animals (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
antineoplastic agents, immunological - therapeutic use (2) 2
apoptosis (2) 2
b cells (2) 2
carcinoma, medullary - genetics (2) 2
carcinoma, medullary - immunology (2) 2
carcinoma, medullary - pathology (2) 2
care and treatment (2) 2
cell biology (2) 2
clinical trials as topic (2) 2
health aspects (2) 2
hemic and lymphatic diseases (2) 2
immunotherapy - methods (2) 2
ipilimumab (2) 2
kidney cancer (2) 2
kidney neoplasms - genetics (2) 2
lymphocytes (2) 2
medical prognosis (2) 2
medical research (2) 2
medicine, experimental (2) 2
melanoma - drug therapy (2) 2
metabolism (2) 2
metastasis (2) 2
middle aged (2) 2
mitochondria (2) 2
neoplasm metastasis (2) 2
nephrectomy (2) 2
programmed cell death 1 receptor - genetics (2) 2
receptor pd-1 (2) 2
renal medullary carcinoma (2) 2
research (2) 2
resistance (2) 2
signal transduction (2) 2
skin neoplasms - drug therapy (2) 2
survival (2) 2
t-lymphocytes - metabolism (2) 2
tumor (2) 2
tumor microenvironment - drug effects (2) 2
usage (2) 2
abridged index medicus (1) 1
adaptive immunity (1) 1
adipocytes (1) 1
adolescent (1) 1
advanced basic science (1) 1
advanced melanoma (1) 1
aged (1) 1
aged, 80 and over (1) 1
agency (1) 1
agents (1) 1
amino acid transport system y+ - metabolism (1) 1
analysis (1) 1
anemia, sickle cell - epidemiology (1) 1
angiogenesis (1) 1
angiogenesis inhibitors - pharmacology (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
anti-ctla-4 (1) 1
anti-pd-1 therapy (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibody (1) 1
antigen (1) 1
antigenic determinants (1) 1
antigens (1) 1
antineoplastic agents - pharmacology (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
atezolizumab (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 05/2018, Volume 78, Issue 10 Supplement, pp. B15 - B15
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 310 - 322
Journal Article
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 04/2018, Volume 32, Issue 4, pp. 190 - 194
Immune checkpoint inhibitors have demonstrated efficacy across many cancer types in numerous clinical trials. However, because patients with preexisting... 
METASTATIC MELANOMA | ANTI-CTLA-4 | ONCOLOGY | ADVANCED MELANOMA | SAFETY | DISORDERS | MYOCARDITIS | CANCER-IMMUNOTHERAPY | PREEXISTING AUTOIMMUNE | ADVERSE EVENTS | IPILIMUMAB
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 11/2018, Volume 128, Issue 11, pp. 4804 - 4820
Journal Article
Journal Article
Stem Cell Reports, ISSN 2213-6711, 03/2018, Volume 10, Issue 3, pp. 684 - 692
Human pluripotent stem cells (hPSCs) maintain a highly fragmented mitochondrial network, but the mechanisms regulating this phenotype remain unknown. Here, we... 
DRP-1 | pluripotent stem cells | OPA1 | MCL-1 | mitochondria | apoptosis | pluripotency | mitochondrial dynamics | MATRIX | FUSION | CONVERSION | BAX | S63845 | FISSION | INHIBITOR | CANCER | DRP1 | CELL & TISSUE ENGINEERING | CELL BIOLOGY | Index Medicus
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 01/2017, Volume 5, Issue 1, pp. 1 - 1
Background: Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait.... 
Renal medullary carcinoma | Renal cell carcinoma | PD-1 | Nivolumab | IMMUNOLOGY | CANCER | CELL CARCINOMA | FEATURES | ANTI-PD-1 THERAPY | MELANOMA | ONCOLOGY | AGENTS | EXPRESSION | Case studies | Chemotherapy | Usage | Care and treatment | Carcinoma | Immunotherapy | Kidney cancer | Cancer | Index Medicus
Journal Article
JAMA Oncology, ISSN 2374-2437, 12/2018, Volume 4, Issue 12, pp. 1721 - 1728
IMPORTANCE Immune checkpoint inhibitors (ICIs) are now a mainstay of cancer treatment. Although rare, fulminant and fatal toxic effects may complicate these... 
SURVIVAL | OPEN-LABEL | OUTCOMES | ONCOLOGY | NIVOLUMAB PLUS IPILIMUMAB | Online First | Original Investigation | Research
Journal Article
JCI insight, ISSN 2379-3708, 06/2017, Volume 2, Issue 12
Cancer cells can inhibit effector T cells (Teff) through both immunomodulatory receptors and the impact of cancer metabolism on the tumor microenvironment.... 
Metabolism | Immunology | MEDICINE, RESEARCH & EXPERIMENTAL | GLUT1 | ACTIVATION | SUPEROXIDE | METABOLISM | IMMUNOSURVEILLANCE | CHECKPOINT | RECEPTOR PD-1 | CANCER | TUMOR MICROENVIRONMENT | LYMPHOCYTES
Journal Article
JCI insight, ISSN 2379-3708, 08/2018, Volume 3, Issue 16
Although a subset of clear cell renal cell carcinoma (ccRCC) patients respond to immune checkpoint blockade (ICB), predictors of response remain uncertain. We... 
Oncology | Immunotherapy | Immunology | MEDICINE, RESEARCH & EXPERIMENTAL | PEMBROLIZUMAB | PD-1 BLOCKADE | GENE-EXPRESSION | CANCER | TUMORS | BAP1
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 2016, Volume 35, Issue 3, pp. 102 - 110
Abstract Background Renal cell cancer (RCC) is a prevalent and lethal disease. At time of diagnosis, most patients present with localized disease. For these... 
Urology | Resistance | mTOR | Angiogenesis | Renal cell carcinoma | Immunotherapy | Immunotherapy - methods | Kidney - blood supply | Kidney - pathology | TOR Serine-Threonine Kinases - metabolism | Humans | Kidney Neoplasms - immunology | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Carcinoma, Renal Cell - immunology | Neovascularization, Pathologic - pathology | Neoplasm Recurrence, Local - immunology | Neoplasm Recurrence, Local - pathology | Receptors, Vascular Endothelial Growth Factor - metabolism | Nephrectomy | Angiogenesis Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Costimulatory and Inhibitory T-Cell Receptors - antagonists & inhibitors | Cytotoxicity, Immunologic - drug effects | Kidney Neoplasms - therapy | Carcinoma, Renal Cell - pathology | Neoplasm Recurrence, Local - therapy | Angiogenesis Inhibitors - pharmacology | Clinical Trials as Topic | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Signal Transduction - drug effects | Neovascularization, Pathologic - drug therapy | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - therapy | Kidney Neoplasms - pathology | Protein Kinase Inhibitors - pharmacology | Chemotherapy | Metastasis | Health aspects | Cancer | Medical research | Carcinoma | Medicine, Experimental | Index Medicus
Journal Article